Tislelizumab clinical trials

Explore recruiting tislelizumab clinical trials.

Recruiting tislelizumab studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Tislelizumab trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

Poland, France, Spain, Italy, Germany, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

MASTER PROTOCOL: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.

France, Italy, Spain, Romania

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)

Romania, Ireland, Germany, Greece, Netherlands, Estonia +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 with Tislelizumab in Patients with Advanced Solid Tumors

France, Spain, Poland, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

France, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma: the ARMANI-2/ENGIC08 trial by GONO

Spain, Germany, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Tislelizumab trials by city

Tislelizumab in Toronto Tislelizumab in Vancouver Tislelizumab in Montreal Tislelizumab in Calgary Tislelizumab in Edmonton Tislelizumab in Ottawa Tislelizumab in Winnipeg Tislelizumab in Quebec City Tislelizumab in Hamilton Tislelizumab in Kitchener Tislelizumab in London Tislelizumab in Halifax Tislelizumab in New York Tislelizumab in Los Angeles Tislelizumab in Chicago Tislelizumab in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease